Quark, Nitto Denko Collaborate on RNAi Drugs for Fibrotic Disease | GenomeWeb

Quark Pharmaceuticals announced this week that it has formed a collaboration with Japan's Nitto Denko to develop siRNA-based drugs for fibrotic diseases.

The deal, Quark said, will combine its expertise and intellectual property related to siRNA design with Nitto Denko's drug-delivery technologies.

The collaboration will have an initial budget in the "double-digit" millions of dollars, and is expected to yield an investigational new drug application by early 2012, Quark added.

Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.